Sodium phosphate OTCs
This article was originally published in The Tan Sheet
Executive Summary
Labels for rectal products containing sodium phosphate/sodium biphosphate will be required to bear sodium content and warnings, according to a final rule published in the Federal Register Nov. 29. Users with certain medical conditions are at risk for an electrolyte imbalance, and high levels of sodium from "both active and inactive ingredients" in the drugs have been implicated in serious adverse events and deaths, FDA notes. The final reg is not expected to have a significant economic impact as it requires "minor relabeling" of fewer than 300 SKUs. No comments were submitted on the proposed rule released in March (1"The Tan Sheet" March 29, 2004, In Brief)...
You may also be interested in...
Sodium phosphate drugs
Rectal products containing sodium phosphate/sodium biphosphate would be required to bear sodium content and warning statements under a proposed rule published by FDA in the March 24 Federal Register. The proposal would apply the same requirements to rectal sodium phosphate drugs that now apply to other OTCs containing sodium. The action responds to concerns that individuals with certain medical conditions are at risk of an electrolyte imbalance when using such products. Comments are requested by June 22...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.